ENA Group 👁️

Prof @Rayazamalik team @OfficialUoM🇬🇧 @WCMQatar🇶🇦 tweets about research on corneal confocal microscopy #CCM👁️ a #biomarker for #neurodegenerative diseases

[WeillCornellQatar @WCMQatar]

WCM-Q clinician scientist @Rayazamalik ranked number one medical researcher in #Qatar for third year running. Congratulations 🥇
@TheLancet @QF @Cornell @WeillCornell @WCMQresearch @CornellRsrch
https://t.co/8boq9RI3gl

[ENA Group 👁️ @GroupENA]

@GPonirakis @WCMQresearch @WCMQatar

[Georgios Ponirakis, PhD 🇺🇦 @GPonirakis]

Read the full study here: https://t.co/ThvQrrP79z

[Georgios Ponirakis, PhD 🇺🇦 @GPonirakis]

Our intuition often misleads us into thinking that general obesity carries the same risk as central obesity. Our study shows that visceral, not subcutaneous, fat drives peripheral #neuropathy through diabetes, hypertension, inflammation, and vascular disease.

[ENA Group 👁️ @GroupENA]

X was once a valuable platform for exchanging ideas. However, with the amplification of misinformation, messages getting buried, and the owner’s retweeting of false content, it is no longer a platform for meaningful conversations.

[Georgios Ponirakis, PhD 🇺🇦 @GPonirakis]

Our latest research on CCM shows that corneal endothelial cell density is significantly reduced in dementia and is associated with cortical gray matter atrophy, while corneal nerve fiber loss is evident in both mild cognitive impairment and dementia. https://t.co/nCTBcZlnQZ

[ENA Group 👁️ @GroupENA]

As AI advances in the analysis of corneal nerve morphology, @Yiannaras et al., from Prof. @Rayazamalik's lab, showed that corneal confocal microscopy (CCM) can distinguish patterns of neurodegeneration in multiple sclerosis and epilepsy. Read more: https://t.co/yOeLlRQASW

[TVST Journal @ARVOtvst]

Ioannis N. Petropoulos et al. @Yiannaras @GroupENA @WCMQresearch report that Corneal Confocal Microscopy Identifies and Differentiates Patients With Multiple Sclerosis and Epilepsy, https://t.co/qXgQG4dUHq.

[Georgios Ponirakis, PhD 🇺🇦 @GPonirakis]

Pleasure to present on neuropathy in prediabetes & diabetes at the 29th TMIMS international symposium: a new era for diagnosis and treatment of #diabetic_neuropathy at the Tokyo Metropolitan Institute of Medical Science. Thank you Dr Odriozola & Dr Sango for the kind invitation!

[Neurodiab @Neurodiab_eu]

Weight management in diabetes: study highlights neuroprotective role of weight loss medications
On Neurodiab website a signaling of articles on #diabeticneuropathy
The 149th NEUROdiab Publication News is by Mette Krabsmark Borbjerg (https://t.co/XVSPHtRKu8…)

[Neurodiab @Neurodiab_eu]

Did you know diabetic neuropathy affects millions of people, leading to distressing complications which affect well-being? This @WorldDiabetesDay, @NEUROdiab_eu Youth Committee is working to improve well-being & reduce the impact of #neuropathy. Together, we can make a difference

[Georgios Ponirakis, PhD 🇺🇦 @GPonirakis]

Honored to celebrate 10 years at Weill Cornell Medicine-Qatar! Proud to contribute to CCM research on neurological disorders with Prof. Malik's team and mentor medical students through the AOC program. Grateful for the journey and the impact we've made together!

[Peripheral Nerve Society (PNS) @PNSociety1]

Choosing diabetes medications that promote weight loss may help reduce nerve damage, improve long-term outcomes for patients. Weight management is crucial in diabetes care.

[Peripheral Nerve Society (PNS) @PNSociety1]

Their study found that people with type 2 diabetes on medications that cause weight gain had worse nerve damage and a greater loss of corneal nerves over time compared to those on weight loss medications.

[Peripheral Nerve Society (PNS) @PNSociety1]

Obesity is a major risk factor for diabetic peripheral neuropathy (DPN) in type 2 diabetes. This study investigated the effect of glucose lowering medication associated with weight change on DPN.

[Peripheral Nerve Society (PNS) @PNSociety1]

Check out the new work from @GPonirakis and colleagues:

Glucose lowering medication associated with weight loss may limit the progression of diabetic neuropathy in type 2 diabetes

https://t.co/5Q02KYnAXJ

#JPNSXHighlights

[Niels Ejskjaer @NielsEjskjaer]

@KMizokamiStout @GerryRaDrGMagic @marcosmatos_ @Lorena_Antunes @VinceSpallone Thank you, all, for a truly great #NeuroDiab2024
🇩🇰🇮🇹
@GPonirakis @Yiannaras @Rayazamalik @johanroeikjer @KenderZoltan @VinniRasmussen @MSjoegaard @MetteBorbjerg

[ENA Group 👁️ @GroupENA]

@MGoonoo @GordonSloan9 @Neurodiab_eu @VinceSpallone @solomon19400 @DrDSelvarajah @Shef_Research @Sheffield_DUK Congrats!

[Bilal Bashir @drbilalbashir]

FCS leads to small fibre nerve damage, clinical neuropathy & early CAN

@Neurodiab_eu
@heartukcharity
@CVD_MFT
@RareDiseases
@CheckOrphan

[Abd Tahrani @AbdTahrani]

Great work by @GPonirakis from Rayaz Malik group showing the variables associated with large and small fibre #neuropathy in people with and without T2 #diabetes . It highlights the links between visceral #obesity and health beyond BMI @Neurodiab_eu #neurodiab2024